ABSTRACT
ObjectiveTo investigate the effect and mechanism of Shuxuetong and its main component hirudin on the apoptosis of cerebellar granule neurons (CGNs) in Sprague-Dawley(SD) rats. MethodsCGNs incubated in vitro for 7 days were divided into survival control group or 25 K group (cultured in medium containing 25 mmol/L KCL) and apoptosis group or 5 K group (cultured in medium containing 5 mmol/L KCL). CGNs were separately treated with proportionally diluted and different concentrations of Shuxuetong (1/50, 1/40, 1/30, 1/20 and 1/10) and the corresponding different concentrations of hirudin (2, 2.5, 3.34, 5 and 10 U / mL). Hoechst staining was performed to analyze the apoptosis. Western blot was used to detect the expression levels of Cleaved Caspase-3, Bim and VEGF. ResultsHoechst staining showed that 5 K group had a higher apoptosis rate than 25 K group. In 25 K group, there was no significant change in the apoptosis rate between neurons treated with different concentrations of Shuxuetong and hirudin, but significant changes was found in 5 K group and the higher the concentration, the lower the apoptosis rate. Western blot results revealed that, compared with control neurons in 5 K group, Shuxuetong injection and hirudin treatments resulted in a decrease of Cleaved Caspase-3 and Bim expression, but an increase of VEGF protein. ConclusionsShuxuetong and its main component hirudin inhibits the apoptosis of CGNs through suppressing proapoptotic BH3-only protein Bim.
ABSTRACT
This study aims to systematically evaluate the efficacy and safety of Shuxuetong Injection in the treatment of stroke in progressive. Randomized controlled trials of Shuxuetong Injection in the treatment of stroke in progressive were searched from CNKI, Wanfang, VIP, CMB, PubMed and EMbase. After strict literature screening, data extraction and quality evaluation, a total of 22 articles were included for analysis by RevMan 5.3. The Meta-analysis showed that Shuxuetong Injection combined with conventional treatment was superior to the conventional treatment alone in the major outcome indicators including effective rate(RR=1.27, 95%CI[1.20, 1.33], Z=9.18, P<0.000 01), deterioration rate(RR=0.38, 95%CI[0.22, 0.68], Z=3.31, P=0.000 9), NIHSS scores(MD=-3.89, 95%CI[-4.34,-3.43], Z=16.83, P<0.000 01), CSS scores(MD=-5.59, 95%CI[-6.42,-4.76], Z=13.20, P<0.000 01) and activity of daily living scores(MD=12.02, 95%CI[10.31, 13.72], Z=13.83, P<0.000 01), mortality during treatment was not increased(RR=0.40, 95%CI[0.13, 1.26], Z=1.56, P=0.12). Moreover, Shuxuetong Injection combined with conventional treatment further reduced the secondary outcome indicators including fibrinogen(MD=-0.35, 95%CI[-0.58,-0.13], Z=3.09, P=0.002), triglyceride(MD=-0.38, 95%CI[-0.67,-0.10], Z=2.65, P=0.008), low density lipoprotein cholesterol(MD=-0.72, 95%CI[-0.83,-0.61], Z=12.64, P<0.000 01), serum hypersensitive C-reactive protein(MD=-4.41, 95%CI[-6.96,-1.86], Z=3.38, P=0.000 7), and interleukin-6(MD=-5.43, 95%CI[-6.91,-3.96], Z=7.22, P<0.000 01). GRADE evaluation results showed that the major outcome indicators had low quality of evidence. Shuxuetong Injection in the treatment of stroke in progressive can improve the clinical effective rate, reduce the deterioration rate, improve the neurological function and activity of daily living, down-regulate the levels of fibrinogen, triglyceride, low density lipoprotein cholesterol and alleviate the inflammatory response. Although most studies have reported no adverse reactions, there are selective reports. The safety of Shuxuetong Injection needs to be further verified by more high-quality randomized controlled trial.
Subject(s)
Humans , Drugs, Chinese Herbal/therapeutic use , Injections , Stroke/drug therapy , Treatment OutcomeABSTRACT
OBJECTIVE: To provide reference for strengthening clinical application of key monitoring drugs and promoting rational drug use in clinic. METHODS: Based on evidence-based medicine, taking key monitoring drugs Shuxuetong injection as example, clinical evidence of domestic and foreign clinical studies were collected. The included literatures were graded according to the quality of GRADE evidence and recommended strength system. Evidence-based medicine evidence for the indications of Shuxuetong injection were evaluated, and criterion for clinical use of Shuxuetong injection was formulated in Huaihua First People’s Hospital (our hospital). RESULTS: The main content of criterion for clinical application of Shuxuetong injection formulated by our hospital was that there was A-level evidence support for acute ischemic cerebral infarction, but it was weakly recommended and only used for adjuvant therapy; there was B-level evidence support for anticoagulation (for preventing DVT), diabetic peripheral nerve lesion, but it was weakly recommended; there was only C-level or D-level evidence support for other indications, it was strongly recommendation against use. CONCLUSIONS: Clinical pharmacists formulate the criterion for clinical application of Shuxuetong injection by evidence quality evaluation method, provide reference for clinical application management of key monitoring drug and play an important effect on rational drug use in clinic.
ABSTRACT
Objective: To explore the influence of the combination of Shuxuetong (SXT) and aspirin on coagulation and fibrinolytic system of rats. Methods: Suture method was applied to establish focal cerebral ischemia-reperfusion injury models in rats. SD rats were randomly divided into sham group, middle cerebral artery occlusion/reperfusion (MCAO/R) group, aspirin group, SXT group, and SXT + aspirin group (S&A). The neurological deficits were assessed according to Longa's grade 5 scoring method. The cerebral edema was detected by measuring the content of water in brain tissue. The volume of cerebral infarction was observed by 2,3,5-Triphenyltetrazolium chloride (TTC) staining. Blood plasma was collected by abdominal aortic method to test maximum platelet aggregation rate and four blood coagulation. CD61, CD62p, 6-keto prostaglandin F1α (6-keto-PGF1α), antithrombin III (AT-III), D-dimer, plasminogen activator inhibitor-1 (PAI-1), tissue factor (TF), tissue plasminogen activator (t-PA), platelet thromboxane B2 (TXB2), and von Willebrand factor (vWF) content in rat plasma were detected by ELISA. Results: SXT combined with aspirin could improve the neurological deficits, alleviate cerebral edema, and decrease the cerebral infarct value. Compared with the sham operation group, fibrinogen (FIB), 6-PGF1α AT-III, and t-PA in model group were significantly decreased; Compared with the model group, the above-mentioned indexes in SXT and aspirin treatment group were significantly increased. The prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), D-dimer, PAI-1, TF, TXB2, and vWF of the model group were significantly increased; The above-mentioned indexes in blood SXT + aspirin treated group were significantly decreased. There was a significant difference between the combined group and SXT group. The maximum concentration of plateletsin aspirin treated rats was significantly decreased, however, MPAR was reversed in SXT + aspirin treated group. Conclusion: SXT combined with aspirin can effectively inhibit platelet activation, regulate the maximum concentration of platelets, and improve coagulation function and fibrinolysis system.
ABSTRACT
Objective@#To explore the therapeutic effects of edaravone, oxiracetam combined with Shuxuetong on cerebral hematoma and improvement of neurological function in patients with cerebral hemorrhage.@*Methods@#A total of 96 patients with cerebral hemorrhage were randomly divided into observation group and control group by the random number table method, with 48 cases in each group.The observation group received intravenous drip of edaravone (4.0g added into 0.9% sodium chloride injection to 250mL, intravenous drip, 1 time/d), oxiracetam(30mg added into 0.9% sodium chloride injection to 100mL solution, 30min intravenous drip, 2 times/d), and Shuxuetong injection(4mL added into 0.9% sodium chloride injection to 250mL, intravenous drip, 1 time/d) on the basis of routine treatment, and the control group was treated with routine treatment for cerebral hemorrhage.The efficacy and safety in the two groups after treatment of 21 days were observed.@*Results@#After treatment, the neurological deficit score and cerebral hematoma volume of the two groups were improved(all P<0.05), but the improvements of the observation group was significantly better than those of the control group[(4.44±3.20)points vs.(10.53±2.86)points, (21.83±3.85)points vs.(26.71±3.49)points, (7.83±5.31)mL vs.(13.74±6.16)mL, t=9.818, 6.506, 5.035, all P<0.01]. The total effective rate of the observation group was higher than that of the control group(87.5% vs.52.1%, χ2=14.740, P<0.05). No drug-related adverse reactions occurred in two groups.@*Conclusion@#The application of oxiracetam and edaravone combined with Shuxuetong injection in patients with cerebral hemorrhage can effectively improve the brain edema and nerve defect, it has a positive significance to promote the patients' recovery after cerebral hemorrhage, and it is worthy of clinical application.
ABSTRACT
Objective To investigate the effect of Shuxuetong (SXT) on promoting collateral circulation formation and enhancing cerebrovascular reserve capacity in mouse models after ischemic stroke.Methods Fifty-eight C57BL/6 mice were randomly divided into blank control group (n=6),SXT group (n=26) and control group (n=26).The mice in the SXT group and control group were subjected to distal middle cerebral artery occlusion (dMCAO) by electrocoagulation,and intraperitoneal administration of SXT (1.5 mL/kg) or equal volume of saline was given 30 min after stroke and repeated every 12 h for the next 3 d.TTC staining was used to assess the volume of infarction one d after ischemic stroke.Adhesive removal tests were performed to evaluate sensorimotor function of the mice before and one,3,7,14,21 and 28 d after stroke,Standardized regional cerebral blood flow (SrCBF) was measured by laser speckle contrast imaging before and one,3,and 7 d after stroke,Immunofluorescence was used to evaluate the numbers of deoxyuridine 5'-monophosphate disodium (BrdU)+,BrdU+/von Willebrand factor (vWF)+ and BrdU+/Laminin+ cells and vessel density 7 d after stroke.The expression levels of total protein kinase (AKT),phosphorylated (p)-AKT,vascular endothelial growth factor (VEGF) and myeloperoxidase (MPO) were explored by Western blotting one d after stroke.Results As compared with those in the control group,the infarction volume of SXT group was significantly smaller one d after stroke,SrCBF was significantly higher 3 and 7 d after stroke,and vessel density was significantly increased and numbers of BrdU+/vWF+ and BrdU+/laminin+ cells in the subventricular zone and peri-infarction region were statistically larger 7 d after stroke (P<0.05).The results of SXT group in behavior experiments were significantly better than those of control group one d after stroke (P<0.05).The levels of p-AKT and VEGF of SXT group were significantly up-regulated,while MPO level was significantly decreased in peri-infarction tissues as compared with those in the control group one d after stroke (P<0.05).Conclusion SXT can promote the formation of collateral circulation and enhance the cerebrovascular reserve canacity.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of Shuxuetong injection combined with rosuvastatin in the treatment of angina pectoris after acute myocardial infarction.METHODS:The information of 68 patients with angina pectoris after acute myocardial infarction were collected retrospectively and divided into control group (34 cases) and study group (34 cases).Based on routine treatment,control group was given Rosuvastatin calcium tablet 10 mg orally,once a day.Study group was additionally given Shuxuetong injection 6 mL added into 0.9% Sodium chloride injection 250 mL intravenously,once a day,on the basis of control group.Both groups were treated for 14 days.Clinical efficacies of 2 groups were observed,and the levels of platelet activation markers (CD62p,CD63,PAC-1,LPA),vascular endothelial growth function indexes (NO,ET-1,VEGF)were observed before and after treatment.The occurrence of ADR was observed.RESULTS:The total response rate of the study group was (94.12%) was significantly higher than that of control group (73.53%),with statistical significance (P<0.05).After treatment,the levels of platelet activation markers,ET-1 and VEGF of 2 groups were significantly lower than before treatment,the study group was significantly lower than the control group;the levels of NO in 2 groups were significantly higher than before treatment,the study group was significantly higher than the control group,with statistical significance (P<0.05).There was no statistical significance in the incidence of ADR between 2 groups (P>0.05).CONCLUSIONS:Based on routine treatment,Shuxuetong injection combined with msuvastatin show significant therapeutic efficacy for angina pectoris after acute myocardial infarction,which can effectively improve vascular endothelial growth function and platelet function,without increasing the occurrence of ADR.
ABSTRACT
To explore the effect of Shuxuetong injection on the pharmacodynamics and pharmacokinetics of warfarin in rats, and to provide reference for rational drug use. In studies on the single dose of warfarin, Wistar rats were randomly divided into four groups: blank control group(group A), Shuxuetong injection group(group B), warfarin control group(group C), and warfarin+Shuxuetong injection group(group D). In studies on the steady state of warfarin, Wistar rats were randomly divided into warfarin control group(group E) and warfarin+Shuxuetong injection group(group F). To investigate the pharmacodynamic effect of Shuxuetong injection on warfarin, prothrombin time(PT) and activated partial thromboplastin time(APTT) were measured by coagulation analyzer, and international normalized ratio(INR) was calculated. To investigate the pharmacokinetic effect of Shuxuetong injection on warfarin, the blood concentrations of S-warfarin and R-warfarin were determined by UPLC-MS/MS combined with technology of chiral chromatographic column, and the related pharmacokinetic parameters were calculated accordingly. The results on the single dose of warfarin showed that Shuxuetong injection markedly increased PT, INR(P<0.01), and APTT(P<0.05). Meanwhile, when Shuxuetong injection was co-administrated with warfarin, it significantly increased PT, INR(P<0.01), and APTT(P<0.05) as compared with warfarin control group. In addition, increased pharmacokinetic parameters including Cmax, AUC0-t and AUC0-∞, prolonged t1/2, and decreased CL/F were observed for S-warfarin and R-warfarin. The results of the steady state of warfarin suggested that Shuxuetong injection significantly increased PT and INR of warfarin(P<0.01), and elevated the plasma concentrations of S-warfarin and R-warfarin when co-administrated with warfarin. These findings indicated that Shuxuetong injection had anticoagulant effect, and would produce pharmacodynamics synergistic action when it was co-administrated with warfarin. Shuxuetong injection also decelerated the metabolism of warfarin, and resulted in pharmacokinetics interaction. Therefore, Shuxuetong injection could significantly increase anticoagulant effect of warfarin, indicating that the combination use of these two drugs should be refrained in order to avoid the risk of bleeding in clinical application. If they need to be used in combination, special attention should be paid to ensure the safety of patients.
ABSTRACT
Objective Using Ginkgo biloba extract injection as control drug,to systematically review the efficacy and safety of Shuxuetong Injection in the treatment of acute cerebral infarction.Methods Database including PubMed,Medline,CNKI,VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about Shuxuetong Injection versus G.biloba extract injection in the treatment of acute cerebral infarction from database setup time to July of 2016.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies.The meta-analysis was conducted by RevMan 5.2 software.Results Total of 11 RCTs,1 338 patients were included.Meta-analysis showed that Shuxuetong Injection was significantly better than G.biloba extract injection in clinical total effective rate [RR =1.17,95%CI(1.11,1.23),P < 0.01],reducing neurological deficit score [MD =-4.46,95%CI (-6.07,-3.25),P < 0.01] and improving life ability score [MD =13.98,95%CI (11.30,16.65),P < 0.01],there was no serious adverse reaction in both groups.Conclusion Current evidence shows that Shuxuetong Injection is effective and safe in the treatment of acute cerebral infarction better than G.biloba extract injection.
ABSTRACT
OBJECTIVE:To investigate the effects of Shuxuetong injection on related indexes of patients with acute myocardial infarction (AMI).METHODS:The data of 156 AMI patients were analyzed retrospectively,and then divided into control group (65 cases) and observation group (91 cases) according to therapy plan.Control group received routine treatment.Observation group was additionally given Shuxuetong injection 6 mL added into 5% Glucose injection 250 mL intravenously,once a day,on the basis of control group.Both groups were given treatment for 5 d.The incidence of vascular recanalization,recanalization time,the incidence of reocclusion as well as LVEF,APTT,PT,FIB,the occurrence of adverse cardiovascular events before and after treatment as well as the occurrence of ADR were observed in 2 groups.RESULTS:The incidence of reocclusion and adverse cardiovascular events in observation group was significantly lower than control group,with statistical significance (P<0.05).There was no statistical significance in the incidence of vascular recanalization,recanalization time or the incidence of ADR between 2 groups (P>0.05).After treatment,the levels of LVEF,APTT and PT in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group.The levels of FIB in 2 groups were significantly lower than before treatment,and the observation group was significantly lower than the control group,with statistical significance (P<0.05).CONCLUSIONS:Based on routine treatment,Shuxuetong injection can reduce the incidence of reocclusion,improve cardiac function and reduce the incidence of adverse cardiovascular events without increasing the occurrence of ADR.
ABSTRACT
Objective To investigate the effects of oxiracetam combined with Shuxuetong injection on hemorheology and serum Hcy levels in patients with cerebral infarction. Methods 60 patients with cerebral infarction were randomly divided into 2 groups, 30 cases in the observation group and were treated with oxiracetam combined with Shuxuetong injection. 30 cases in the control group were treated with Shuxuetong injection. The hemorheology and serum Hcy levels in the two groups were compared. Results After treatment, the hemorheological indexes and serum Hcy levels in the observation group were lower than those in the control group (P<0.05). The treatment effect of the observation group was better than that of the control group (P<0.05). The scores of neurological deficits in the observation group were significantly better than those in the control group (P<0.05). The number of complications in the observation group was 2 cases, the incidence of complications was 6.7%, which were significantly lower than 9(30.0%) in the control group, the differences between the two groups was statistically significant (P<0.05). Conclusion The application of oxiracetam combined with Shuxuetong injection in patients with cerebral infarction can effectively improve the hemorheology and reduce the serum Hcy level.
ABSTRACT
Objective Study the effect of Shuxuetong combined with Shenmai injection on serum CPR, SOD and MDA levels in elderly patients with acute myocardial infarction after PCI, and to analyze the main adverse cardiovascular events. Methods Chose 88 patients with PCI from June 2015 to June 2016 in our hospital, they were randomly divided into observation group and control group, 44 cases in each group. The control group was given conventional drug therapy before PCI. On the basis of this, the observation group was treated with Shuxuetong combined with Shenmai intravenous injection before PCI. The treatment of the two groups continued to one week after PCI. Compared the levels of serum malondialdehyde (MDA), superoxide dismutase (SOD) and hypersensitive C-reactive protein (hs-CRP) between the two groups before and after PCI, and compared the levels of coagulation factor, dynamic electrocardiogram, Left ventricular ejection fraction (LVEF) and myocardial infarct size, and compared the incidence of arrhythmia and major adverse cardiovascular events after PCI. Results The levels of serum MDA and hs-CRP in the observation group were significantly lower than those in the control group (P<0.05), the level of SOD was significantly higher than the control group (P<0.05); The level of coagulation factor in the observation group was significantly higher than that in the control group (P<0.05). The myocardial infarct size, the number of ischemic attacks, the decrease of ST segment and the descending time of ST segment were significantly lower than those of the control group (P<0.01). The incidence of MACE was significantly lower in the observation group than in the control group (P<0.05). Conclusion Conventional treatment combined with Shuxuetong combined with Shenmai injection can effectively prevent ischemia-reperfusion injury in elderly patients with AMI, improve cardiac function and reduce the main adverse cardiovascular events after PCI, which reflects the combination of traditional Chinese and western medicine Advantages, worthy of clinical use.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of Shuxuetong injection combined with alprostadil in the treat-ment of acute cerebral infraction(ACI). METHODS:A total of 123 ACI patients selected from our hospital during Mar. 2014-Sept. 2016 selected as research subjects were divided into observation group (62 cases) and control group (61 cases) according to ran-dom number table. Control group was additionally given Alprostadil injection 2 mL+0.9% Sodium chloride injection 100 mL, ivgtt,qd,on the basis of routine treatment. Observation group was additionally given Shuxuetong injection 6 mL+0.9% Sodium chloride injection 250 mL,ivgtt,qd,on the basis of control group. Both groups were treated for 2 weeks. MPV,FIB content, hemorheology indexes,neurologic impairment degree score before and after treatment as well as clinical efficacy,the occurrence of ADR were compared between 2 groups. RESULTS:Before treatment,there was no statistical significance in MPV,FIB content, hemorheology indexes or neurologic impairment score between 2 groups (P>0.05). Compared with before treatment,MPV,FIB content,hemorheology indexes and modified Rankin scale of 2 groups were all decreased significantly;Barthel index and NIHSS scores were increased significantly,and each aspect of observation group was better than that of control group,with statistical sig-nificance(P<0.05). Total response rate of observation group was 95.16%,which was significantly higher than 85.25% of control group,with statistical significance(P<0.05). No severe ADR was found in 2 groups. CONCLUSIONS:Shuxuetong injection com-bined with alprostadil can significantly improve the neurological function of ACI patients,improve hypercoagulable state by reduc-ing MPV and FIB content,and have good therapeutic efficacy and safety.
ABSTRACT
AIM:To investigate the curative effect of Shuxuetong injection combined with intravitreal injection of ranibizumab and laser photocoagulation in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).METHODS:Totally 70 patients (70 affected eyes) with ME secondary to BRVO treated from January 2015 to December 2016 were randomly divided into the control group and the observation group by random number table method,35 patients (35 affected eyes) in each group.The control group were treated by intravitreal injection of ranibizumab and laser photocoagulation,and on the basis,the observation group were treated with Shuxuetong injection.The clinical curative effect and complications were compared between the two groups.At 1wk,1 and 3mo after treatment,the best corrected visual acuity (BCVA) and central retinal thickness (CRT)were checked again.RESULTS:The total effective rate of treatment in the observation group was slightly higher than that in the control group (91% vs 80%;P>0.05) while the markedly effective rate in the observation group was higher than that in the control group (43% vs20%;P<0.05).At 1wk,1 and 3mo after treatment,BCVA and CMT in the two groups decreased (P<0.05),and they were lower in the observation group than the control group at the same time point (P<0.05).There was no significant difference in the incidence of complications between the two groups (P>0.05).CONCLUSION:The treatment of ME secondary to BRVO with Shuxuetong injection combined with intravitreal injection of ranibizumab and laser photocoagulation can effectively reduce CRT and improve visual acuity,with high safety.
ABSTRACT
This study adopted multi-center and large sample design to understand the incidence, characteristics and other information about adverse reaction of Shuxuetong injection. In 54 medical institutions, use of Shuxuetong injection of entire treatment period was monitored, including patients' general information, diagnostic information, medication, adverse reaction/event information, etc. Sixty four cases of adverse reactions in 32 546 patients was monitored, adverse rate was 0.197%, mainly characterized by skin itching, rash, flu-like, dyspnea, palpitations, headache, chest tightness and other allergic reactions. Adverse reaction occurred mainly in elderly patients and medication was consistent with the instruction. Based on these results, safety of Shuxuetong injection in clinical application is excellent.
ABSTRACT
Objective To investigate the effects of Shuxuetong on hemodynamics and serum sICAM-1,IL-6,TNF-α in patients with cerebral infarction.Methods A hundred patients with cerebral infarction were randomly divided into observation group and control group from Jan 2011 to Jan 2015.Fifty patients in control group were treated with conventional therapy alone and 50 patients in observation group were treated with conventional therapy combined with intravenous injection with Shuxuetong.The changes of hemodynamics were observed before and after treatment and the levels of serum sICAM-1,IL-6,TNF-α were detected by enzyme linked immunosorbent assay (ELISA).Results No statistical significance was found in hemodynamics of control group before and after treatment (P >0.05).The indexes of hemodynamics in observation group were significantly improved compared with those in observation group before treatment and those in control group after treatment (P< 0.05).The levels of serum sICAM-1,IL-6,TNF-α were significantly reduced in two groups after treatment (P <0.01) and the levels of serum sICAM-1,IL-6,TNF-α after treatment were significantly lower in observation group than those in control group (P<0.01).Conclusion Shuxuetong can effectively improve the indexes ofhemodynamics and reduce the levels of serum sICAM-1,IL-6 and TNF-α.It has a positive effect on the treatment of cerevral infarction.
ABSTRACT
OBJECTIVE:To observe the efficacy and safety of Shuxuetong injection in the treatment of acute cerebral infarc-tion (ACI). METHODS:110 patients with ACI were randomly divided into control group and observation group. Control group was given mannitol,aspirin,atorvastatin,antidiabetic drugs and other conventional treatment;observation group was additionally given Shuxuetong injection 6 ml adding into 0.9% Sodium chloride solution 250 ml by intravenous infusion,3 times a day. The ef-ficacy in 2 groups was evaluated after 15 d,and the National Institute of Health Stroke Scale(NIHSS)score,neuron specific eno-lase(NSE),high-sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor-α(TNF-α)levels before and after treatment and the incidence of adverse reactions in 2 groups were recorded. RESULTS:After treatment,NIHSS score,NSE,hs-CRP and TNF-αin 2 groups were significantly lower than before,and observation group was lower than control group,the differences were statisti-cally significant(P<0.05);total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P<0.05). There was no obvious adverse reactions in 2 groups during treatment. CONCLUSIONS:Based on the conventional treatment,Shuxuetong injection has good efficacy and safety in the treatment of ACI.
ABSTRACT
Objective To observe the clinical efficacy and safety of Shuxuetong in treatment of paroxysmal atrial fibril-lation in patients with chronic pulmonary heart disease. Methods A randomized single-blinded study was performed. A to-tal of 91 patients with paroxysmal atrial fibrillation and chronic pulmonary heart disease were randomly divided into treat-ment group (n=45) and control group (n=46). The treatment group was received Shuxuetong and clopidogrel treatment for 14 days. The control group was given routine treatment plus clopidogrel 75 mg orally. The average time of cardioversion of parox-ysmal atrial fibrillation was detected within 48 hours. The cardioversion rate of paroxysmal atrial fibrillation and the total effi-ciency were detected after14 days. The serum D-Dimer was detected before and 14 days after treatment . Liver and kidney function and adverse drug reactions were also detected. Results There was no significant difference in average time of car-dioversion of paroxysmal atrial fibrillation in 48 h between two groups (h:12.62±2.32 vs 13.32±2.25,t=1.461). The cardiover-sion rates were 86.67%(39/45) and 82.22%(37/45) at 48 h and 14 d in treatment group, which were significantly higher than those of control group [69.56%(32/46) and 60.87(28/46)]. The D-Dimer at 14 d after treatment was significantly lower in treatment group [(2.05±0.34)mg/L] than before treatment[(2.61±0.27)mg/L], also than that of control group[(2.53±0.31)mg/L]. There were no abnormal liver and kidney function and no adverse reactions between two groups. Conclusion Shuxuetong can significantly prevent the recurrence of paroxysmal atrial fibrillation in patients with chronic pulmonary heart disease, and help to reduce the risk of thromboembolism. It is safe and effective.
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of Shuxuetong combined with acupuncture in the treat-ment of patients with stroke during recovery period. METHODS:80 patients with stroke during recovery period were selected and divided into observation group and control group,with 40 cases in each group according to random number table method. Control group received acupuncture,6 times a week. Observation group was additionally given Shuxuetong injection 6 ml added into 0.9% Sodium chloride injection 250 ml,ivgtt,qd,for one month. Clinical efficacy of 2 groups were observed as well as in-tracranial [arteriae cerebri anterior (ACA),middle cerebral artery (MCA),basilar artery (BA)] blood flow rate,neurological deficit score(NIHSS),cognitive ability(MMSE)score,Fugl-Meyer activity score and Fugl-Meyer balance score before and af-ter treatment. The occurrence of ADR was compared. RESULTS:Total effective rate of observation group was 95.0%,which was significantly higher than that of control group(70.0%),with statistical significance(P<0.05). Compared with before treatment, blood flow rate of ACA and MCA were increased significantly in observation group after treatment,and were higher than those of control group with statistical significance (P<0.05). NIHSS,MMSE,Fugl-Meyer activity score and Fugl-Meyer balance score of 2 groups improved significantly after treatment,the observation group was better than the control group,with statistical signifi-cance(P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:Shuxuetong combined with acupuncture show signif-icant therapeutic efficacy,and improve intracranial blood flow rate and neurologic function with good safety.
ABSTRACT
Objective:To observe expression level change of miRNA?126 in the myocardial tissue of rats with myocardial infarction and to observe the influence of Shuxuetong injection. Methods:Myocardial infarction model was established in 80 SD rats, 60 surviv?al rats were randomly divided into Shuxuetong group and model group, the other 30 rats were randomly selected as control group. After the success of the modeling, Shuxuetong group received Shuxuetong injection treatment, model group and control group received same amount of normal saline. Real?time quantitative PCR was used to detect miRNA?126 expression levels in rat myocardial tissue at dife?rent time after operation. Results: After 7 days and 14 days, miRNA?126 expression levels in rats myocardial tissue in Shuxuetong group and model group were significantly lower than that in the control group ( P<0?05) , but there was no difference between the two groups. After 14 days, miRNA?126 expression levels in the Shuxuetong group were higher than that after 7 days ( P<0?05) . Conclu?sions:miRNA?126 in 7 days after myocardial infarction significantly reduced. With the passing of time, miRNA?126 expression levels increased gradually and Shuxuetong can increase the expression levels of miRNA?126 .